Back to resultsTo Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients
Primary Purpose
Migraine
Status
Completed
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
Erenumab
Placebo
PACAP-38 Challenge Agent
Sponsored by
About this trial
This is an interventional prevention trial for Migraine focused on measuring Migraine, Headache, Migraine Headache, Headache, Migraine, Amgen
Eligibility Criteria
Inclusion Criteria:
- Adults ≥ 18 to ≤ 45 years of age upon entry into screening
- History of migraine headaches without aura for ≥ 6 months prior to screening according to the International Headache Society (IHS) International Classification of Headache Disorders (ICHD-II) (Headache Classification Committee of the International Headache Society, 2004) based on medical records and/or patient self-report
- Migraine frequency: ≥ 1 and ≤ 5 migraine days per month in each of the 3 months prior to screening
Exclusion Criteria:
- History of migraine with aura, cluster headache or hemiplegic migraine headache according to the IHS Classification ICHD-II (Headache Classification Committee of the International Headache Society, 2004) based on medical records and/or patient self-report
- ≥ 6 migraine days per month in the last 3 months prior to study enrollment and during screening period
- Other headache disorders (except for episodic tension-type headache <5 days/month)
Sites / Locations
- Research Site
- Research Site
- Research Site
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Other
Placebo Comparator
Experimental
Arm Label
PACAP-38 Challenge Agent
Placebo
Erenumab
Arm Description
In Part A, 4 cohorts of 2 to 5 participants sequentially received an intravenous infusion of 10 picomol/kilogram/minute (pmol/kg/minute) PACAP-38 for 2.5, 5, 7.5 and 10 minutes each in order to determine the dose for Part B.
Participants were randomized to receive matching erenumab placebo by intravenous administration over 30 minutes on day 1. On day 8 participants were administered the dose of PACAP-38 determined from Part A of the study (100 pmol/kg) and were followed up for 11 weeks.
Participants were randomized to receive 140 milligrams (mg) erenumab by intravenous administration over 30 minutes on day 1 in Part B. On day 8 participants were administered the dose of PACAP-38 determined from Part A of the study (100 pmol/kg) and were followed up for 11 weeks.
Outcomes
Primary Outcome Measures
Number of Participants With a MLA Within 24 Hours of Challenge Agent Infusion
On day 1 of the double-blind randomization phase participants received 140 mg intravenous erenumab over 30 minutes or matching placebo. On day 8, participants received 10 mol/kg/minute PACAP-38 over 10 minutes and were observed for 24 hours after PACAP-38 infusion.
A MLA was defined as fulfilling 1 of the 2 criteria:
Headache with at least 2 of the following characteristics: unilateral location, pulsating quality, moderate or severe pain intensity, aggravated by/causing avoidance of routine physical activity. Additionally, during the headache at least 1 of the following: nausea and/or vomiting, photophobia or phonophobia.
Headache described as mimicking usual migraine attack treated with triptan.
Secondary Outcome Measures
Number of Participants With a Headache Within 24 Hours of Challenge Agent Infusion
On day 1 of the double-blind randomization phase participants received 140 mg intravenous erenumab over 30 minutes or matching placebo. On day 8, participants received 10 mol/kg/minute PACAP-38 over 10 minutes and were observed for 24 hours after PACAP-38 infusion.
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
TEAEs were summarised for days 1 to 7 after the participants received placebo or erenumab infusion on day 1 of the Part B randomization phase. TEAEs were also summarized from day 8 to end of study (EOS) after participants had received both investigational product (placebo or erenumab) and the second dose of PACAP-38 on day 8.
Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at Day 1, Day 8 and EOS
Systolic and diastolic BP was assessed during Part B of the study, and the mean change from baseline is presented for the last measurements taken following administration of placebo or erenumab on day 1 (1 hour post-dose), and following administration of PACAP-38 on day 8 (8 hours post-dose). The mean change from baseline is also presented for the EOS assessment.
Mean Change From Baseline in Heart Rate at Day 1, Day 8 and EOS
Heart rate was assessed during Part B of the study, and the mean change from baseline is presented for the last measurements taken following administration of placebo or erenumab on day 1 (1 hour post-dose), and following administration of PACAP-38 on day 8 (8 hours post-dose). The mean change from baseline is also presented for the EOS assessment.
Mean Change From Baseline in Respiratory Rate at Day 1, Day 8 and EOS
Respiratory rate was assessed during Part B of the study, and the mean change from baseline is presented for the last measurements taken following administration of placebo or erenumab on day 1 (1 hour post-dose), and following administration of PACAP-38 on day 8 (8 hours post-dose). The mean change from baseline is also presented for the EOS assessment.
Mean Change From Baseline in Temperature at Day 1, Day 8 and EOS
Temperature was assessed during Part B of the study, and the mean change from baseline is presented for the last measurements taken following administration of placebo or erenumab on day 1 (1 hour post-dose), and following administration of PACAP-38 on day 8 (8 hours post-dose). The mean change from baseline is also presented for the EOS assessment.
Mean Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) at Day 8, Day 9 and EOS
ALP, ALT and AST were assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.
Mean Change From Baseline in Total Bilirubin at Day 8, Day 9 and EOS
Total bilirubin was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.
Mean Change From Baseline in Blood Urea at Day 8, Day 9 and EOS
Blood urea was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.
Mean Change From Baseline in Creatine Kinase at Day 8, Day 9 and EOS
Creatine Kinase was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.
Mean Change From Baseline in Creatinine at Day 8, Day 9 and EOS
Creatinine was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.
Mean Change From Baseline in Direct Bilirubin at Day 8, Day 9 and EOS
Direct bilirubin was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.
Mean Change From Baseline in Eosinophil Count at Day 8, Day 9 and EOS
Eosinophil count was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.
Mean Change From Baseline in Blood Glucose at Day 8, Day 9 and EOS
Blood glucose was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.
Mean Change From Baseline in Hemoglobin A1C (Fraction of 1) at Day 8, Day 9 and EOS
Hemoglobin A1C was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.
Pharmacokinetics (PK): Mean Erenumab Serum Concentration at 1 Hour (C1h)
The mean serum erenumab concentration at 1 hour post-dose on day 1 of Part B randomization phase is presented.
PK: Mean Area Under the Concentration-time Curve From Time 0 to 84 Days Post-dose (AUC84d)
The mean AUC84d for erenumab for the Part B randomization phase is presented.
Number of Participants With Anti-Erenumab Antibodies
Participants were tested for binding antibodies and neutralizing antibodies at baseline and following treatment with erenumab.
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters
At baseline, 12-lead ECGs were performed in a standardized method, in triplicate, and approximately 30 seconds apart, prior to blood draws or other invasive procedures. Single ECGs were performed from Day 1 to EOS. ECG results were reviewed by the investigator and classified as: normal, abnormal not clinically significant or abnormal, clinically significant. The number of participants with abnormal, clinically significant changes in ECG results at EOS are presented.
Number of Participants With Clinically Significant Changes in Physical Parameters
Physical examinations were performed by an investigator and any abnormal findings, judged to be clinically significant were recorded as an AE. The number of participants with clinically significant changes in physical parameters at EOS are presented.
Number of Participants With Clinically Significant Changes in Neurological Assessments
Neurological examinations including assessment of cranial nerves, motor system, sensory system (including testing for pain sensation [pin prick], light touch sensation [brush], von Frey, and vibratory sense), reflexes, and cerebellar function were performed by the investigator and classified as normal or abnormal. Any abnormal findings, judged by the investigator to be clinically significant, were recorded as an AE. The number of participants with clinically significant changes in neurological assessments at EOS are presented.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02542605
Brief Title
To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients
Official Title
Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced Migraine-like Attacks in Migraine Patients
Study Type
Interventional
2. Study Status
Record Verification Date
February 2019
Overall Recruitment Status
Completed
Study Start Date
November 11, 2015 (Actual)
Primary Completion Date
September 28, 2017 (Actual)
Study Completion Date
November 8, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Amgen
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced Migraine-like Attacks in Migraine Patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Migraine
Keywords
Migraine, Headache, Migraine Headache, Headache, Migraine, Amgen
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
35 (Actual)
8. Arms, Groups, and Interventions
Arm Title
PACAP-38 Challenge Agent
Arm Type
Other
Arm Description
In Part A, 4 cohorts of 2 to 5 participants sequentially received an intravenous infusion of 10 picomol/kilogram/minute (pmol/kg/minute) PACAP-38 for 2.5, 5, 7.5 and 10 minutes each in order to determine the dose for Part B.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants were randomized to receive matching erenumab placebo by intravenous administration over 30 minutes on day 1. On day 8 participants were administered the dose of PACAP-38 determined from Part A of the study (100 pmol/kg) and were followed up for 11 weeks.
Arm Title
Erenumab
Arm Type
Experimental
Arm Description
Participants were randomized to receive 140 milligrams (mg) erenumab by intravenous administration over 30 minutes on day 1 in Part B. On day 8 participants were administered the dose of PACAP-38 determined from Part A of the study (100 pmol/kg) and were followed up for 11 weeks.
Intervention Type
Drug
Intervention Name(s)
Erenumab
Other Intervention Name(s)
AMG 334, Aimovig™
Intervention Description
Administered once on day 1 of Part B of the study by intravenous infusion.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Administered once on day 1 of Part B of the study by intravenous infusion.
Intervention Type
Drug
Intervention Name(s)
PACAP-38 Challenge Agent
Other Intervention Name(s)
Pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38)
Intervention Description
Administered by intravenous infusion during Part A of the study for dose selection for Part B.
Administered by intravenous infusion on day 8 in Part B as a challenge agent to induce a migraine-like attack.
Primary Outcome Measure Information:
Title
Number of Participants With a MLA Within 24 Hours of Challenge Agent Infusion
Description
On day 1 of the double-blind randomization phase participants received 140 mg intravenous erenumab over 30 minutes or matching placebo. On day 8, participants received 10 mol/kg/minute PACAP-38 over 10 minutes and were observed for 24 hours after PACAP-38 infusion.
A MLA was defined as fulfilling 1 of the 2 criteria:
Headache with at least 2 of the following characteristics: unilateral location, pulsating quality, moderate or severe pain intensity, aggravated by/causing avoidance of routine physical activity. Additionally, during the headache at least 1 of the following: nausea and/or vomiting, photophobia or phonophobia.
Headache described as mimicking usual migraine attack treated with triptan.
Time Frame
Part B randomization phase day 8 plus 24 hours.
Secondary Outcome Measure Information:
Title
Number of Participants With a Headache Within 24 Hours of Challenge Agent Infusion
Description
On day 1 of the double-blind randomization phase participants received 140 mg intravenous erenumab over 30 minutes or matching placebo. On day 8, participants received 10 mol/kg/minute PACAP-38 over 10 minutes and were observed for 24 hours after PACAP-38 infusion.
Time Frame
Part B randomization phase day 8 plus 24 hours.
Title
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Description
TEAEs were summarised for days 1 to 7 after the participants received placebo or erenumab infusion on day 1 of the Part B randomization phase. TEAEs were also summarized from day 8 to end of study (EOS) after participants had received both investigational product (placebo or erenumab) and the second dose of PACAP-38 on day 8.
Time Frame
Part B randomization phase day 1 until EOS (up to 12 weeks).
Title
Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at Day 1, Day 8 and EOS
Description
Systolic and diastolic BP was assessed during Part B of the study, and the mean change from baseline is presented for the last measurements taken following administration of placebo or erenumab on day 1 (1 hour post-dose), and following administration of PACAP-38 on day 8 (8 hours post-dose). The mean change from baseline is also presented for the EOS assessment.
Time Frame
Part B randomization phase baseline and day 1, day 8 and EOS (week 12).
Title
Mean Change From Baseline in Heart Rate at Day 1, Day 8 and EOS
Description
Heart rate was assessed during Part B of the study, and the mean change from baseline is presented for the last measurements taken following administration of placebo or erenumab on day 1 (1 hour post-dose), and following administration of PACAP-38 on day 8 (8 hours post-dose). The mean change from baseline is also presented for the EOS assessment.
Time Frame
Part B randomization phase baseline and day 1, day 8 and EOS (week 12).
Title
Mean Change From Baseline in Respiratory Rate at Day 1, Day 8 and EOS
Description
Respiratory rate was assessed during Part B of the study, and the mean change from baseline is presented for the last measurements taken following administration of placebo or erenumab on day 1 (1 hour post-dose), and following administration of PACAP-38 on day 8 (8 hours post-dose). The mean change from baseline is also presented for the EOS assessment.
Time Frame
Part B randomization phase baseline and day 1, day 8 and EOS (week 12).
Title
Mean Change From Baseline in Temperature at Day 1, Day 8 and EOS
Description
Temperature was assessed during Part B of the study, and the mean change from baseline is presented for the last measurements taken following administration of placebo or erenumab on day 1 (1 hour post-dose), and following administration of PACAP-38 on day 8 (8 hours post-dose). The mean change from baseline is also presented for the EOS assessment.
Time Frame
Part B randomization phase baseline and day 1, day 8 and EOS (week 12).
Title
Mean Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) at Day 8, Day 9 and EOS
Description
ALP, ALT and AST were assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.
Time Frame
Part B randomization phase baseline and day 8, day 9 and EOS (week 12).
Title
Mean Change From Baseline in Total Bilirubin at Day 8, Day 9 and EOS
Description
Total bilirubin was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.
Time Frame
Part B randomization baseline and day 8, day 9 and EOS (week 12).
Title
Mean Change From Baseline in Blood Urea at Day 8, Day 9 and EOS
Description
Blood urea was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.
Time Frame
Part B randomization baseline and day 8, day 9 and EOS (week 12).
Title
Mean Change From Baseline in Creatine Kinase at Day 8, Day 9 and EOS
Description
Creatine Kinase was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.
Time Frame
Part B randomization baseline and day 8, day 9 and EOS (week 12).
Title
Mean Change From Baseline in Creatinine at Day 8, Day 9 and EOS
Description
Creatinine was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.
Time Frame
Part B randomization baseline and day 8, day 9 and EOS (week 12).
Title
Mean Change From Baseline in Direct Bilirubin at Day 8, Day 9 and EOS
Description
Direct bilirubin was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.
Time Frame
Part B randomization baseline and day 8, day 9 and EOS (week 12).
Title
Mean Change From Baseline in Eosinophil Count at Day 8, Day 9 and EOS
Description
Eosinophil count was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.
Time Frame
Part B randomization baseline and day 8, day 9 and EOS (week 12).
Title
Mean Change From Baseline in Blood Glucose at Day 8, Day 9 and EOS
Description
Blood glucose was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.
Time Frame
Part B randomization baseline and day 8, day 9 and EOS (week 12).
Title
Mean Change From Baseline in Hemoglobin A1C (Fraction of 1) at Day 8, Day 9 and EOS
Description
Hemoglobin A1C was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.
Time Frame
Part B randomization baseline and day 8, day 9 and EOS (week 12).
Title
Pharmacokinetics (PK): Mean Erenumab Serum Concentration at 1 Hour (C1h)
Description
The mean serum erenumab concentration at 1 hour post-dose on day 1 of Part B randomization phase is presented.
Time Frame
Part B randomization phase 1 hour post-dose day 1.
Title
PK: Mean Area Under the Concentration-time Curve From Time 0 to 84 Days Post-dose (AUC84d)
Description
The mean AUC84d for erenumab for the Part B randomization phase is presented.
Time Frame
Part B randomization phase baseline and 84 days post-dose.
Title
Number of Participants With Anti-Erenumab Antibodies
Description
Participants were tested for binding antibodies and neutralizing antibodies at baseline and following treatment with erenumab.
Time Frame
Part B randomization phase baseline and EOS.
Title
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters
Description
At baseline, 12-lead ECGs were performed in a standardized method, in triplicate, and approximately 30 seconds apart, prior to blood draws or other invasive procedures. Single ECGs were performed from Day 1 to EOS. ECG results were reviewed by the investigator and classified as: normal, abnormal not clinically significant or abnormal, clinically significant. The number of participants with abnormal, clinically significant changes in ECG results at EOS are presented.
Time Frame
Part B randomization phase baseline and EOS.
Title
Number of Participants With Clinically Significant Changes in Physical Parameters
Description
Physical examinations were performed by an investigator and any abnormal findings, judged to be clinically significant were recorded as an AE. The number of participants with clinically significant changes in physical parameters at EOS are presented.
Time Frame
Part B randomization phase baseline and EOS.
Title
Number of Participants With Clinically Significant Changes in Neurological Assessments
Description
Neurological examinations including assessment of cranial nerves, motor system, sensory system (including testing for pain sensation [pin prick], light touch sensation [brush], von Frey, and vibratory sense), reflexes, and cerebellar function were performed by the investigator and classified as normal or abnormal. Any abnormal findings, judged by the investigator to be clinically significant, were recorded as an AE. The number of participants with clinically significant changes in neurological assessments at EOS are presented.
Time Frame
Part B randomization phase baseline and EOS.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adults ≥ 18 to ≤ 45 years of age upon entry into screening
History of migraine headaches without aura for ≥ 6 months prior to screening according to the International Headache Society (IHS) International Classification of Headache Disorders (ICHD-II) (Headache Classification Committee of the International Headache Society, 2004) based on medical records and/or patient self-report
Migraine frequency: ≥ 1 and ≤ 5 migraine days per month in each of the 3 months prior to screening
Exclusion Criteria:
History of migraine with aura, cluster headache or hemiplegic migraine headache according to the IHS Classification ICHD-II (Headache Classification Committee of the International Headache Society, 2004) based on medical records and/or patient self-report
≥ 6 migraine days per month in the last 3 months prior to study enrollment and during screening period
Other headache disorders (except for episodic tension-type headache <5 days/month)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
MD
Organizational Affiliation
Amgen
Official's Role
Study Director
Facility Information:
Facility Name
Research Site
City
Anaheim
State/Province
California
ZIP/Postal Code
92801
Country
United States
Facility Name
Research Site
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Facility Name
Research Site
City
Leiden
ZIP/Postal Code
2333 CL
Country
Netherlands
12. IPD Sharing Statement
Links:
URL
http://www.amgentrials.com
Description
AmgenTrials clinical trials website
Learn more about this trial
To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients
We'll reach out to this number within 24 hrs